CSX 36.74 CSX Corp $CSX Hit a 52 week high of 36.84 Closing

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
CSX 36.74 CSX Corp $CSX Hit a 52 week high of 36.84 Closing the day 09:45 at 36.74 +0.03 +0.08% With a day low of 36.50 and a total volume of 291,083.

CSX Recent Posts: http://investorshangout.com/CSX-Corp-CSX-50640/

CSX CSX Corp Recent Headline News

CSX CFO Reiterates Expectations And Strategy For Long-Term Value Creation
PR Newswire - 9 mins ago
CSX (NYSE: CSX) has taken a number of actions to overcome the transition in the energy markets in recent years, emerging a stronger company that is better positioned to capitalize on momentum across nearly all the markets it serves, Chief Financial Officer Fredrik Eliasson told investors and analysts at the Baird Global Industrials Conference today in Chicago.
CSX: 36.51 (-0.20)

Railroads Grow Faster Than The Economy
Michael Hooper - at Seeking Alpha - Tue Nov 11, 6:07AM CST

NSC: 116.01 (-0.62), SPY: 203.60 (-0.58), CNI: 70.72 (-0.17), KSU: 123.77 (-1.07), CP: 209.12 (-0.89), IYT: 161.92 (-0.37), CSX: 36.51 (-0.20), BRK.B: 145.14 (+0.19), UNP: 120.18 (-1.06)

Look for Shares of CSX to Potentially Pullback after Yesterday's 3.13% Rise
Comtex SmarTrend(R) - Mon Nov 10, 4:00PM CST
CSX (NYSE:CSX) traded in a range yesterday that spanned from a low of $35.60 to a high of $36.58. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $35.58 on volume of 7.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CSX: 36.51 (-0.20)

CSX Rises 3.13% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Nov 10, 4:00PM CST
CSX (NYSE:CSX) traded in a range yesterday that spanned from a low of $35.60 to a high of $36.58. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $35.58 on volume of 7.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CSX: 36.51 (-0.20)

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Nov 07, 7:19PM CST
Next week Cramer will be watching earnings from WhiteWave Foods, DR Horton and Wal-Mart, among many others.
DHI: 23.97 (+0.02), KMI: 38.59 (+0.05), HK: 3.03 (+0.01), KSS: 56.99 (+0.76), GE: 26.47 (+0.09), LMT: 186.84 (-0.28), AVAV: 29.57 (+0.11), WMT: 79.01 (unch), SNE: 20.55 (-0.16), M: 60.18 (+1.59), SDRL: 21.53 (-0.07), T: 35.38 (+0.28), W: 21.98 (-1.68), OPK: 8.36 (-0.17), QCOM: 70.36 (+0.72), TWTR: 39.87 (+0.28), EPR: 56.98 (-0.53), AAPL: 110.58 (+0.88), HSIC: 128.99 (-0.48), CSCO: 25.13 (-0.02), WFM: 47.33 (-0.16), CY: 10.15 (unch), MU: 32.95 (-0.25), SWKS: 61.48 (+0.51), IRM: 37.97 (+0.14), BAC: 17.16 (-0.16), MO: 48.83 (-0.45), CSX: 36.51 (-0.20), WWAV: 36.17 (-0.32), GILD: 106.74 (-1.27), TXN: 50.87 (-0.44), BPL: 79.36 (+0.78), JCP: 7.44 (+0.24), JWN: 71.10 (+0.62), BABA: 116.60 (+2.06)

Next Resistance Level for CSX (CSX) is $35.60
Comtex SmarTrend(R) - Fri Nov 07, 10:39AM CST
Shares of CSX (NYSE:CSX) opened today above their pivot of $35.00 and have already reached the first level of resistance at $35.36. Investors may be interested in a cross of the next upside pivot targets of $35.60 and $36.19.
CSX: 36.51 (-0.20)

October Railroad Report: Keep Rolling On
Investor RockieK - at Seeking Alpha - Fri Nov 07, 10:00AM CST

NSC: 116.01 (-0.62), CNI: 70.72 (-0.17), KSU: 123.77 (-1.07), CP: 209.12 (-0.89), CSX: 36.51 (-0.20), BRK.A: 217,801.00 (+448.30), UNP: 120.18 (-1.06)

Dividend Growth Strategy: Take The Beaten Path Or Road Less Traveled?
Adam Aloisi - at Seeking Alpha - Thu Nov 06, 1:52PM CST

KO: 42.72 (+0.21), BDX: 128.47 (-0.29), HD: 97.67 (-0.47), AMT: 99.32 (-0.18), AMGN: 161.67 (-0.75), O: 46.41 (-0.42), MO: 48.83 (-0.45), CSX: 36.51 (-0.20), LUV: 39.06 (-0.31), T: 35.38 (+0.28), JNJ: 108.44 (-0.47), RCL: 66.94 (-0.84), V: 250.15 (+0.42), QCOM: 70.36 (+0.72), MCD: 95.12 (-0.02), PG: 89.67 (unch), MSFT: 48.71 (-0.16), CVX: 117.91 (-0.53), AAPL: 110.58 (+0.88), WAG: 67.00 (-0.50)

CSX Concludes Racketeering and Fraud Litigation Against Asbestos Lawyers
PR Newswire - Thu Nov 06, 11:42AM CST
CSX Transportation today announced that it has resolved the final stages of its racketeering and fraud lawsuit against asbestos attorneys Robert N. Peirce Jr. and Louis A. Raimond, and radiologist Dr. Ray Harron. As part of the settlement, the West Virginia jury's verdict stands and CSX will be paid $7.3 million to satisfy the trial court judgment entered against the lawyers and doctor on September 25, 2013, and in resolution of disputed motions for attorney fees and costs.
CSX: 36.51 (-0.20)

Dividend Contenders, Future Champions Or Future Failures: Part 5
Stan Stafford - at Seeking Alpha - Wed Nov 05, 7:30PM CST

NSC: 116.01 (-0.62), CNI: 70.72 (-0.17), CSX: 36.51 (-0.20)

CSX Names Kellen Riley South Carolina Industrial Development Manager
PR Newswire - Wed Nov 05, 12:00PM CST
CSX (NYSE: CSX) today announced the appointment of Kellen Riley as its South Carolina Industrial Development Manager. In this role, Riley will be responsible for managing existing customer partnerships, helping to locate rail-served industries along the CSX network in South Carolina and identifying new development sites throughout the state.
CSX: 36.51 (-0.20)

CSX Corporation Chief Financial Officer to Address Baird's 2014 Industrial Conference
PR Newswire - Wed Nov 05, 9:00AM CST
Fredrik Eliasson, CSX Corporation (NYSE: CSX) executive vice president and chief financial officer, will address Baird's 2014 Industrial Conference in Chicago, Wednesday, November 12, at 8:00 a.m. Central time / 9:00 a.m. Eastern time.
CSX: 36.51 (-0.20)

Watch for CSX to Potentially Rebound After Falling 2.18% Yesterday
Comtex SmarTrend(R) - Tue Nov 04, 3:55PM CST
CSX (NYSE:CSX) traded in a range yesterday that spanned from a low of $34.58 to a high of $35.28. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $35.02 on volume of 17.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CSX: 36.51 (-0.20)

CSX Falls 2.18% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Nov 04, 3:55PM CST
CSX (NYSE:CSX) traded in a range yesterday that spanned from a low of $34.58 to a high of $35.28. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $35.02 on volume of 17.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CSX: 36.51 (-0.20)

Federal Highway Administration Approves Construction Alternative for CSX's Virginia Avenue Tunnel Project
PR Newswire - Tue Nov 04, 3:39PM CST
The Federal Highway Administration has approved a preferred construction alternative for CSX's Virginia Avenue Tunnel project, enabling CSX to complete the tunnel's design and initiate the construction permitting process. The decision marks the completion of an extensive environmental review of the project conducted jointly with the District of Columbia Department of Transportation, which incorporates three years of input from residents, businesses and government agencies in the southeast Washington, D.C., neighborhood around the tunnel.
CSX: 36.51 (-0.20)

CSX (CSX) Crosses Pivot Point Support at $35.04
Comtex SmarTrend(R) - Tue Nov 04, 10:12AM CST
CSX (NYSE:CSX) has opened bearishly below the pivot of $35.39 today and has reached the first level of support at $35.04. Investors may be interested in a cross of the next downside pivot targets of $34.70 and $34.01.
CSX: 36.51 (-0.20)

Financial Results, Facility Opening, and Management Changes - Research Reports on Norfolk, Cardinal, CSX, Viacom and Carnival
PR Newswire - Tue Nov 04, 8:10AM CST
Today, Analysts Review released its research reports regarding Norfolk Southern Corp. (NYSE: NSC), Cardinal Health Inc. (NYSE: CAH), CSX Corporation (NYSE: CSX), Viacom, Inc. (NASDAQ: VIAB) and Carnival Corporation (NYSE: CCL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7672-100free.
NSC: 116.01 (-0.62), CCL: 40.21 (-0.42), CAH: 79.50 (-0.10), CSX: 36.51 (-0.20), VIAB: 69.58 (+0.05)

CSX Corp. Once Again Tops List of Florida's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking
Marketwired - Tue Nov 04, 5:15AM CST
CSX Corp. claims six top-ranked positions in the 2015 All-America Executive Team survey, Institutional Investor's annual poll of investors and sell-side analysts regarding America's top executives, IR professionals and IR programs.
CSX: 36.51 (-0.20)

Looking At Rails Through A Warren Buffett Lens For 2015
Dividends For The Long Haul - at Seeking Alpha - Mon Nov 03, 6:25PM CST

NSC: 116.01 (-0.62), CSX: 36.51 (-0.20), UNP: 120.18 (-1.06)

Green Signal for 3 Transportation Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 10:11AM CDT
The transportation sector is stepping on the gas to zoom ahead of other sectors this earnings season.
AAWW: 41.12 (-0.49), TK: 54.05 (+0.05), FLY: 12.70 (+0.30), CNI: 70.72 (-0.17), KSU: 123.77 (-1.07), JBLU: 12.42 (-0.53), CP: 209.12 (-0.89), CSX: 36.51 (-0.20), UPS: 108.02 (-0.74), UAL: 53.78 (-0.88)

CSX Corp. (CSX) Stock Research Links

CSX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 294

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 637

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 281

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 385

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 254

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
"blog__more"> More News Articles